High-Flow Nasal Cannula Market Developments and Forecast by 2027

The High Flow Nasal Cannula market was valued at US$ 4,390.74 million in 2018 and it is projected to reach US$ 11,198.78 million by 2027; it is expected to grow at a CAGR of 11.1% from 2019 to 2027.

High flow nasal cannula (HFNC) is an oxygen supply system that is capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute. HFNC has been gaining attention as alternative respiratory support for critically ill patients. HFNC is used for the treatment of respiratory conditions such as asthma and COPD, however useful for treating hypercapnic respiratory failure and mild to moderate hypoxemic respiratory failure can be done using high flow nasal cannula. The growth of the High Flow Nasal Cannula market is attributed to the rising incidences if asthma and COPD across the globe and rising geriatric population. However, the side effects associated with the use of high-flow nasal cannula is expected to hamper the growth of the market.

Published Report - High-Flow Nasal Cannula Market: Strategic Insights

The High Flow Nasal Cannula market is expected to witness substantial growth post-pandemic. The High Flow Nasal Cannula  market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for High Flow Nasal Cannula Market

Market Insights

Growing Applications of High Flow Nasal Cannula in Healthcare to Drive High Flow Nasal Cannula Market Growth

The number of cases of asthma and COPD has been growing all over the world at a substantial rate. In recent years, the number of smokers and the levels of air pollution in developed, as well as developing countries, is increasing across the globe. Asthma is a medical condition where the airways swell and narrow and also produces mucus. This further leads to wheezing, coughing, and recurrent attacks of breathlessness, which differ in severity and frequency from person to person. 

According to the World Health Organization estimates, there are approximately 235 million people suffering from asthma around the world. Moreover, the Centers for Disease Control and Prevention (CDC) reported, approximately19 million adults in the United States (18 years of age or above) are currently suffering from asthma, which accounts for almost 7.7% of the total adult population. Whereas, about 6.2 million patients below 18 years of age have asthma, which accounts for 8.4% of the total children population. Also, according to the WHO estimates published during December 2016, there were around 383,000 deaths due to asthma in 2015.

Similarly, the number of patients suffering from COPD across the globe is growing. Chronic obstructive pulmonary disease (COPD) is a long term lung disease that causes shortness of breath, chest tightness, chronic cough, respiratory infections, wheezing, and others. According to the WHO Global Burden of Disease Study report, in 2016, globally, around 251 million people were suffering from COPD. Furthermore, the report also mentioned that approximately 3.17 million deaths across the globe were caused due to COPD in the year 2015, which accounts for almost 5% of all deaths in 2015. In recent years, the prevalence of COPD in developed nations is also increasing. For instance, COPD is the third leading cause of death in the United States, and over 11 million patients in the US have been diagnosed with COPD. Thus, the rising prevalence of respiratory conditions such as asthma and COPD and increasing applications of high flow nasal cannula in treating such diseases is anticipated to fuel the growth of the high flow nasal cannula market across the globe at an exponential rate.

COPD and asthma are senescence condition, which leads to gradual complications. Asthma in older adults is a critical condition that often goes unnoticed, as per the Asthma and Allergy Foundation of America (AAFA). According to the Office of Disease Prevention and Health Promotion (ODPHP), approximately 23 million people in the U.S. have some form of asthma, most of which include the older population. Older people with asthma often need high doses of medication, in spite of mild asthma attacks. Hence, they are more likely to suffer from respiratory failure much faster as compared to the younger population. Also, COPD can appear at any age. However, it is more prevalent in the older population and can be fatal. The aging population is growing exponentially worldwide. 

According to a report of the United Nations (2017), there were approximately 962 million people aged 60 or over across the globe in 2017 and was projected to reach 425 million by 2050. The number of the elderly population is expected to grow significantly in Africa, followed by North America, Latin America & the Caribbean, and the Asia Pacific region.

The elderly people are more likely to have COPD and asthma than younger people, and the effect of the disease on quality of life is particularly deep in this population. With increase in the number of geriatric population, the prevalence of the COPD and asthma will increase significantly. Also, the number of hospital admissions and number of surgeries will increase. Thus, the demand for high flow nasal cannula market is expected to increase in the forecast period.

Component-Based Insights

In terms of component, the High Flow Nasal Cannula market is segmented into air oxygen blender, nasal cannula, heated inspiratory circuit, active humidifier. Active humidifier segment held the largest share of the market. Moreover, this segment is also expected to register the highest CAGR of 11.7% in the market during the forecast period.

High Flow Nasal Cannula Market, by Component – 2018 and 2027

Application-Based Insights

Based on application, the High Flow Nasal Cannula market is segmented into bronchiectasis, acute respiratory failure, acute heart failure, and chronic obstructive pulmonary disease. In 2018, the chronic obstructive pulmonary disease (COPD) accounted for the largest market share in the global highflow nasal cannula market by application.

End User-Based Insights

In terms of end user, the High Flow Nasal Cannula market is segmented into ambulatory care centers, hospitals, long term care centers. In 2018, the hospitals segment held the largest share of the market. Moreover, the segment is also expected to register the highest CAGR of 11.4% in the market during the forecast period.

The High Flow Nasal Cannula market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

High Flow Nasal Cannula Market – by Component

• Air Oxygen Blender
• Nasal Cannula
• Heated Inspiratory Circuit
• Active Humidifier

High Flow Nasal Cannula Market – by Application

• Bronchiectasis
• Acute Respiratory Failure
• Acute Heart Failure
• Chronic Obstructive Pulmonary Disease (COPD)

High Flow Nasal Cannula Market – by End User

• Hospitals
• Ambulatory Care Centers
• Long-Term Care Centers

High Flow Nasal Cannula Market – by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA
• South America and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Fisher & Paykel Healthcare Limited.
• ResMed
• Great Group Medical Co., Ltd.
• Salter Labs
• TNI Medical Ag
• Mek-Ics Co., Ltd.
• Flexicare Medical Limited
• Vapotherm
• Teleflex Incorporated
• Hamilton Medical

Published Report - High-Flow Nasal Cannula Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - High-Flow Nasal Cannula Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.